Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Statement

15 Jan 2014 07:00

RNS Number : 6625X
Plant Health Care PLC
15 January 2014
 

 

15 January 2014

 

 

 

 

Plant Health Care plc

 

("Plant Health Care" or "the Company")

 

Trading Update

 

 

Plant Health Care plc, ("PHC"), a leading provider of novel patent-protected biological products to the global agriculture markets, provides the following update for the 12 months to 31 December 2013 ahead of its full year results announcement on 24 March 2014.

 

Trading continues to be in line with the Board's expectations. The full year results will reflect the implementation of the new strategy that was announced following the US$20 million fundraising completed in April 2013.

 

In September's interim results statement, PHC reported significant progress, most notably:

 

· New management in place in new headquarters in Raleigh, North Carolina

· New Development and Commercial agreements with Arysta LifeScience and others

· Moved to expanded research facilities in Seattle which enhanced and accelerated investment in the discovery and evaluation of a new generation of Harpin products

 

In the second half of the year, implementation of the new strategy has continued:

 

· In July, the Company's agreement with Monsanto was discontinued and PHC recovered its globally licensed rights to Harpin as a seed treatment.

· In September, Jeff Hovey was appointed Chief Financial Officer. Since joining, he has completed the transfer of the Company's administration and accounting functions from Pittsburgh to Raleigh. The Pittsburgh office was closed on 31 December 2013.

· In November, PHC completed the sale of its non-core European distribution activities while retaining a core capability in the UK and Spain to enable the continued exploitation of Europe, South Africa and certain other non-American markets.

 

All of these actions have been achieved in line with the targets set out at the time of the fundraising.

 

The full year results will reflect these changes and will set out the contribution from our continuing activities and those relating to discontinued and non-core activities.

 

~ ENDS ~

 

For further information, please contact:

 

Plant Health Care plc

Paul Schmidt, Chief Executive Officer

Tel: +1 919 926 1600

Liberum Capital - Nomad and Broker

Clayton Bush / Thomas Bective

Tel: +44 (0) 20 3100 2222

Powerscourt

Sophie Moate / Nick Dibden

Tel: +44 (0) 20 7250 1446

 

About Plant Health Care plc: Plant Health Care is a leading provider of patent protected biological products aimed at the agriculture industry that are environmentally beneficial. Through the commercialisation of these products, Plant Health Care is capitalising on current long-term trends toward natural systems and biological products for plant care and soil and water management.

 

Further information is available at: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFSALLISLIS
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.